Zymeworks, Inc.
1385 West 8th Avenue
Suite 540
Vancouver
British Columbia
V6H 3V9
Canada
Tel: 604-678-1388
Website: http://www.zymeworks.com/
Email: info@zymeworks.com
About Zymeworks, Inc.
Established in 2003 with offices in Vancouver, BC and Seattle, WA, Zymeworks is a fast-growing, clinical-stage biotechnology company dedicated to the research, development and commercialization of best-in-class therapeutic bispecific antibodies and antibody drug conjugates for the treatment of cancer, autoimmune and inflammatory diseases. Zymeworks is proud to have active collaborations with Merck, Eli Lilly, Celgene, GlaxoSmithKline, Daiichi-Sankyo, Johnson & Johnson, Leo Pharma and BeiGene and is committed to making a meaningful difference in the lives of patients everywhere.
281 articles about Zymeworks, Inc.
-
Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research & Development Day
10/3/2022
Zymeworks Inc. today announced that management will participate in upcoming investor conferences.
-
Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile
9/26/2022
Zymeworks Inc. is pleased to announce that a second independent proxy advisory firm, Institutional Shareholder Services Inc., has recommended shareholders vote FOR the Company’s plan to become a Delaware corporation.
-
Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR Redomicile
9/16/2022
Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that independent proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) has recommended that Zymeworks shareholders vote FOR the Company’s plan to become a Delaware corporation (the “Redomicile”).
-
Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual Congress
9/12/2022
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today presented preliminary results from the company’s Phase 1 clinical trial evaluating zanidatamab zovodotin (ZW49) for the treatment of HER2-positive tumors.
-
Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware
9/8/2022
Zymeworks Inc. announced that the proxy statement and related materials, dated September 2, 2022 for its special meeting of securityholders have been filed publicly and are being mailed to securityholders.
-
Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers
9/4/2022
Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced the release of an abstract by ESMO with preliminary results from the company’s Phase 1 study of zanidatamab zovodotin, an investigational novel bispecific HER2 targeted antibody-drug conjugate.
-
Paul Moore took over as CSO at Zymeworks in July at a pivotal time for the company. He spoke with BioSpace about his ambitions.
-
Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results
8/4/2022
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the second quarter ended June 30, 2022.
-
Zymeworks Announces Participation in Upcoming Investor Conferences - Aug 01, 2022
8/1/2022
Zymeworks Inc., a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, announced that management will participate in an upcoming investor conference.
-
Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris
7/25/2022
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that data from the company’s Phase 1 study of zanidatamab zovodotin (ZW49), an investigational novel bispecific HER2 targeted antibody-drug conjugate, were accepted for an oral presentation at the European Society for Medical Oncology Congress 2022 in Paris.
-
Zymeworks Reports Inducement Grant to New Chief Scientific Officer
7/22/2022
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the “NYSE Rule”), an equity inducement award to Dr. Paul Moore, Zymeworks’ new Chief Scientific Officer.
-
Zymeworks to Host Second Quarter Results Conference Call
7/21/2022
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its second quarter 2022 financial results after market close on August 4th , 2022.
-
Zymeworks Announces Plan to Become a Delaware Corporation
7/15/2022
Zymeworks Inc. today announced its intention to become a Delaware corporation (“New Zymeworks”), subject to receipt of necessary shareholder, stock exchange, and court approvals.
-
Another C-suite change at Zymeworks was announced Monday, with the appointment of Paul Moore, Ph.D. as chief scientific officer.
-
Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
6/27/2022
Dr. Moore will lead Zymeworks’ Early Research & Development Group responsible for advancing the Company’s next-generation of multispecific antibody programs and antibody drug conjugate (ADC) programs into clinical studies.
-
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
6/10/2022
Zymeworks Inc., a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, announced that its board of directors has adopted a limited-duration shareholder rights plan.
-
Zymeworks Announces Participation in Upcoming Investor Conference
5/27/2022
Zymeworks Inc., a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, announced that management will participate in an upcoming investor conference:
-
Zymeworks increased its stake in the company to 6.9%, slightly under 4 million shares, and options with shares popped 13% after the original bid and are up another 10%.
-
Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022
5/26/2022
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced new clinical data for the HER2‑targeted bispecific antibody zanidatamab in both HER2-positive breast cancer and gastric/gastroesophageal junction adenocarcinoma.
-
Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
5/20/2022
Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal.